Can an immunotherapy combo boost remission in a rare lymphoma?
NCT ID NCT05254899
First seen Aug 18, 2026 · Last updated Aug 18, 2026
Summary
This phase II trial is testing whether adding the immunotherapy drug tislelizumab to a chemotherapy regimen (pegaspargase, gemcitabine, and oxaliplatin) plus radiation can improve outcomes for people with early-stage, intermediate- or high-risk extranodal NK/T-cell lymphoma. The study will measure how many patients achieve a complete response after three cycles of the induction treatment, and will also track survival, side effects, and quality of life over two to five years. Participants must have newly diagnosed, stage I-II disease with at least one risk factor, such as elevated LDH or stage II disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tislelizumab (an anti-PD-1 immunotherapy) combined with pegaspargase, gemcitabine, oxaliplatin, and involved-site radiation therapy
- What this could lead to
- If successful, this combination could become a more effective first-line treatment for early-stage high-risk NK/T-cell lymphoma, potentially increasing the chance of complete remission and long-term survival.
- What could go wrong
- This is a phase II trial with a small number of participants, so results may not be definitive. The combination may cause significant side effects, and the complete response rate might not be better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can diet and vitamin c supercharge rectal cancer treatment?
- Can tracking thousands of patients unlock the secrets of rare EBV-driven blood cancers?
- New cocktail approach aims to wipe out High-Risk rectal cancer without surgery
- Immunotherapy combo may outperform chemo in rare lymphoma
- Could a prostate cancer drug help fight a tough breast cancer?
- New drug combo aims to keep High-Risk nasopharyngeal cancer at bay